PITTSBURGH--(BUSINESS WIRE)--Dec. 20, 2002--Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. District Court for the District of New Jersey has granted summary judgment in Mylan's favor on the issue of non-infringement of Organon's Remeron^® patent No. 5,977,099.

Mirtazapine is the generic equivalent of Remeron, a $490 million product indicated for the treatment of major depression. Mylan received tentative Food and Drug Administration (FDA) approval for Mirtazapine Tablets in 15 mg, 30 mg and 45 mg strengths on January 15, 2002. Mylan will launch the product upon receipt of final FDA approval.

Mylan Laboratories Inc. is a leading pharmaceutical company that develops, manufactures and markets generic and proprietary prescription products. Mylan has two operating segments that market an extensive line of generic and branded products through four business units: Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Bertek Pharmaceuticals Inc. For more information about Mylan, visit www.mylan.com.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. We refer you to the risk factors and other disclosures contained in our periodic SEC filings.

We undertake no duty to update our forward-looking statements, even though our situation may change in the future.

--30--ac/ny*

CONTACT:	Mylan Laboratories Inc., Pittsburgh
	Patricia Sunseri, 412/232-0100